Trials / Completed
CompletedNCT00232063
Long-term Study of Ciclosporin for Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 20 Years – 64 Years
- Healthy volunteers
- —
Summary
In patients with severe adult atopic dermatitis, the safety and efficacy of OL27-400MEPC will be assessed by repeating oral administration at a dose of 3 mg/kg/day (2-5 mg/kg/day) in 2 divided doses daily for 8-12 weeks and recovery until 52 weeks after starting treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ciclosporin |
Timeline
- Start date
- 2004-05-01
- Primary completion
- 2005-11-01
- First posted
- 2005-10-04
- Last updated
- 2011-11-02
Source: ClinicalTrials.gov record NCT00232063. Inclusion in this directory is not an endorsement.